Form 8-K - Current report:
SEC Accession No. 0001683168-24-007710
Filing Date
2024-11-07
Accepted
2024-11-07 09:00:08
Documents
15
Period of Report
2024-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K xenetic_8k.htm   iXBRL 8-K 27461
2 PRESS RELEASE xenetic_ex9901.htm EX-99.1 14926
6 GRAPHIC image_001.gif GRAPHIC 5333
  Complete submission text file 0001683168-24-007710.txt   229032

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE xbio-20241101.xsd EX-101.SCH 3021
4 XBRL LABEL FILE xbio-20241101_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE xbio-20241101_pre.xml EX-101.PRE 24169
17 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_8k_htm.xml XML 3572
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37937 | Film No.: 241433427
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)